MRUS

Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates

Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update

Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting

Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference

Merus N.V. Announces Proposed Public Offering of Common Shares

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial